"We are adding a very innovative bioanalytical tool to our Lab Products & Services portfolio that will enable our customers to obtain lab results much faster and reduce the time to clinic for virus-based pharmaceuticals," said Michael Melingo, member of the Sartorius Group Executive Committee. Added Robert Kline, ViroCyt President and CEO, "The worldwide reach and outstanding reputation of Sartorius will accelerate the adoption of the Virus Counter technology. ViroCyt is proud to join the Sartorius family and the partnership is a positive development for our customers, employees and shareholders."
ViroCyt, Inc. was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. Additional information can be found at http://www.virocyt.com.
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than EUR1.1B in 2015. More than 6,200 people work at the Group's 50 manufacturing and sales sites, serving customers around the globe. To learn more, visit https://www.sartorius.com/.
Dr. Michael Artinger
Vice President, Marketing & Strategic Partnering